GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alkermes, Inc. (ALKS) [hlAlert]

Rating:
Neutral ALKS

Alkermes, Inc. (ALKS) rated Neutral with price target $11 by Robert W. Baird

Posted on: Friday,  Mar 6, 2009  8:25 AM ET by Robert W. Baird

Alkermes, Inc. (ALKS) rated
Neutral with price target $11 by Robert W. Baird.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Deep, comprehensive coverage is essential to your success. And with nearly 100 research professionals covering over 500 U.S. companies, our reputation for trusted, award-winning, in-depth analysis with a strong commitment to objective, fundamental research speaks for itself.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/6/2009 8:25 AM Hold
None
8.39 11.00
as of 12/31/2009
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/23/2008 8:25 AM Hold
None
12.54 12.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy